Picard Medical, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Picard Medical, Inc. (PMI) on March 19, 2026. The company is incorporated in Delaware and operates as an emerging growth company. Its common stock trades on The NYSE American, LLC under the symbol "PMI". The report primarily addresses a Regulation FD disclosure regarding a clinical milestone.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative financial data.
Material Changes
There are no material financial changes reported in this filing. The significant event disclosed is a clinical achievement: a patient was sustained by the SynCardia Total Artificial Heart for 119 days while awaiting a donor transplant.
Guidance, Outlook, and Management Commentary
Management highlighted the 119-day survival duration as a key demonstration of the SynCardia Total Artificial Heart's efficacy as a bridge-to-transplant therapy. The company issued a press release on March 19, 2026, to announce this milestone. No specific financial guidance, future outlook, or discussion of risks and contingencies is included in this specific filing text.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for additional clinical details regarding the 119-day patient case.
- Review the company's most recent 10-K or 10-Q filings for current financial performance, as this 8-K contains no financial data.
- Confirm the regulatory status and approval pathways for the SynCardia Total Artificial Heart in relevant markets.
- Monitor subsequent filings for any updates on patient outcomes or new clinical trial data.